Targeting APOC3 in the familial chylomicronemia syndrome

New England Journal of Medicine

Volumn 371, Issue 23, 2014, Pages 2200-2206

  Gaudet, Daniel ^a,b   Brisson, Diane ^a,b   Tremblay, Karine ^a,b   Alexander, Veronica J ^c   Singleton, Walter ^c   Hughes, Steven G ^c   Geary, Richard S ^c   Baker, Brenda F ^c   Graham, Mark J ^c   Crooke, Rosanne M ^c   Witztum, Joseph L ^d  

^a CHICOUTIMI HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ISIS PHARMACEUTICALS   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; CHYLOMICRON; ISIS 304801; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROTEIN INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; OLIGONUCLEOTIDE;

ADVERSE OUTCOME; APOC3 GENE; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; DRUG MECHANISM; FAMILIAL CHYLOMICRONEMIA SYNDROME; HUMAN; HYPERTRIGLYCERIDEMIA; INHIBITION KINETICS; INJECTION SITE REACTION; LIPOPROTEIN BLOOD LEVEL; OUTCOME ASSESSMENT; STEADY STATE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; DEFICIENCY; GENETICS; HYPERLIPOPROTEINEMIA TYPE I; MUTATION;

APOLIPOPROTEIN C-III; HUMANS; HYPERLIPOPROTEINEMIA TYPE I; LIPOPROTEIN LIPASE; MUTATION; OLIGONUCLEOTIDES; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84918803944     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1400284     Document Type: Article

References (31)

1. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency In: Scriver CR, Beaudet AI, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill, 2000:2789-816.
2. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012;272:185-96.
3. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992;37:249-73.
4. Tremblay K, Méthot J, Brisson D, Gaudet D. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011;5:37-44.
5. Christian JB, Bourgeois NE, Lowe KA. Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008. J Cardiovasc Med (Hagerstown) 2011;12:714-22.
6. Gaudet D, Méthot J, Déry S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an openlabel trial. Gene Ther 2013;20:361-9.
7. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
8. Brown WV, Brunzell JD, Eckel RH, Stone NJ. Severe hypertriglyceridemia. J Clin Lipidol 2012;6:397-408.
9. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008;114:611-24.
10. Graham MJ, Lee RG, Bell TA III, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013;112:1479-90.
11. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269:23610-6.
12. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249: 790-3.
13. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010;362:1082-9.
14. Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322: 1702-5.
15. Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res 2011;52:189-206.
16. Atzmon G, Rincon M, Schechter CB, et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol 2006;4(4):e113.
17. Zheng C. Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease. Curr Opin Lipidol 2014;25:35-9.
18. LaRosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970;41:57-62.
19. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972;46:375-82.
20. Kinnunen PK, Ehnolm C. Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett 1976; 65:354-7.
21. Yao Z, Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol 2012;23: 206-12.
22. Aalto-Set.l. K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-900.
23. Lee RG, Crosby J, Baker BF, Graham MJ, Crooke RM. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J Cardiovasc Transl Res 2013;6:969-80.
24. Lee RG, Graham MJ, Fu W, et al. Antisense suppression of serum apoC-III improves hypertriglyceridemia and insulin sensitivity in multiple species. Diabetes 2013;62:Suppl 1A:LB14. abstract.
25. Alexander V, Gaudet D, Cheng W, et al. An antisense inhibitor of apolipoprotein C-III significantly decreases apolipoprotein C-III, triglycerides, very-low-density lipoprotein cholesterol and particle number, and increases high-density lipoprotein cholesterol and particle number in hypertriglyceridemic patients on a fibrate. J Am Coll Cardiol 2014;12:Suppl:63. abstract.
26. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 1979;28:1001-10.
27. Fredenrich A, Giroux LM, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J Lipid Res 1997;38:1421-32.
28. Mendivil CO, Rimm EB, Furtado J, Chiuve SE, Sacks FM. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011;124:2065-72.
29. The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-offunction mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-31.
30. Jrgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj.rg-Hansen A. Lossof-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41.
31. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.